Who are Rivaroxaban Oral Tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hympavzi, Eliquis, Xarelto, Heparin Sodium In Plastic Container, Innohep (tinzaparin), ACL/FOR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rivaroxaban-oral-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rivaroxaban Oral Tablet — Competitive Intelligence Brief

Rivaroxaban Oral Tablet (Rivaroxaban Oral Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct Factor Xa inhibitor. Area: Cardiovascular.

marketed Direct Factor Xa inhibitor Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rivaroxaban Oral Tablet (Rivaroxaban Oral Tablet) — Swiss Paraplegic Research, Nottwil. Rivaroxaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rivaroxaban Oral Tablet TARGET	Rivaroxaban Oral Tablet	Swiss Paraplegic Research, Nottwil	marketed	Direct Factor Xa inhibitor	Factor Xa
Hympavzi	MARSTACIMAB	Pfizer Inc	marketed	Monoclonal Antibody	Factor Xa	2025-01-01
Eliquis	apixaban	Bristol-Myers Squibb	marketed	Factor Xa inhibitor	Factor Xa (FXa)	2012-01-01
Xarelto	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anti-coagulant	Antithrombin III, Factor Xa, Factor IIa	1939-01-01
Innohep (tinzaparin)	Innohep (tinzaparin)	Ottawa Hospital Research Institute	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and thrombin (via antithrombin III enhancement)
ACL/FOR	ACL/FOR	Queen's University	marketed	Factor Xa inhibitor	Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Direct Factor Xa inhibitor class)

Ahmed AbdelMoneim Hassan Ali · 1 drug in this class
Bayer · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
Charles University, Czech Republic · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
Florida Orthopaedic Institute · 1 drug in this class
McMaster University · 1 drug in this class
Rennes University Hospital · 1 drug in this class
Swiss Paraplegic Research, Nottwil · 1 drug in this class
Taejoon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rivaroxaban Oral Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban-oral-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab